In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.
Mult Scler Relat Disord
; 72: 104616, 2023 Apr.
Article
en En
| MEDLINE
| ID: mdl-36933299
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
COVID-19
/
Esclerosis Múltiple
Límite:
Female
/
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article